Choose a folder
Publication milestones for DISCOVER
The DISCOVER study team is pleased to announce that a manuscript describing findings from the DISCOVER Electronic Medical Records (EMR) data analysis has been published in Diabetes, Obesity and Metabolism.
This study, an integral part of the global DISCOVER programme, utilized EMR data from 10 256 patients with type 2 diabetes who initiated second-line glucose-lowering therapy between 2011 and 2014 in Germany and the UK. After 6 months of follow-up, changes in glycated haemoglobin (HbA1c) levels were assessed in relation to selection of second-line therapy and to other patient variables.
The main finding from the study was that there was no difference between the second-line therapies with regard to changes in HbA1c levels over 6 months in patients with type 2 diabetes (Table 1). Results of a multivariate analysis assessing additional determinants of HbA1c change suggested that initiating therapy within 6 months of diabetes diagnosis and being of an older age might increase 6-month HbA1c reductions in patients initiating second-line therapies. These results offer insight into real world effects of diabetes treatments; it will be interesting to see whether the 1-year global DISCOVER data, expected in 2018, support these findings.
To read the article, please click here. For further publication updates, please keep visiting the DISCOVER website.
Table 1. HbA1c changes after 6 months according to second-line therapies initiated
aFor patients with mean baseline HbA1c level (8.68%), estimated from a linear regression model with slope −0.45% (0.01) per unit increase in HbA1c for baseline HbA1c < 9.0% and −0.86% (0.02) per unit increase in HbA1c for baseline HbA1c ≥ 9.0%.
DPP-4i, dipeptidylpeptidase-4 inhibitor; HbA1c, glycated haemoglobin; MET, metformin; SU, sulphonylurea.